Events & Presentations
Current Events
Citi Global Healthcare Conference
New York, NY – December 5–6, 2018
3rd Annual World Preclinical Congress
Lisbon, Portugal – November 27–30, 2018
Evercore ISI 2018 HealthConX Conference
Boston, MA – November 27, 2018
Evercore ISI Madrigal
Webinar – November 19, 2018 – Slides
Credit Suisse Annual Healthcare Conference
Scottsdale, AZ – November 14, 2018 – Webcast Link – Slides
AASLD – The Liver Meeting 2018 – Analyst/Investor KOL Event
San Francisco, CA – November 12, 2018 – Webcast link – Slides
AASLD – The Liver Meeting 2018 – Plenary Presentation
San Francisco, CA – November 12, 2018 – Slides
NASH Summit Europe 2018
Frankfurt, Germany – October 22–24, 2018
Roth NASH Investor Conference
New York, NY – October 17, 2018
Presentations
LDL cholesterol, apolipoprotein B, lipoprotein(a), apolipoprotein CIII and triglyceride lowering by MGL-3196, a thyroid hormone receptor beta selective agonist, in a 12 week study in HeFH patients
August 21, 2018
MGL-3196, a β-Selective Thyroid Hormone Receptor (THR) Agonist, Demonstrates Metabolic, Anti-inflammatory and Anti-fibrotic Benefits in a Long-term High Fat Diet (HFD) Mouse NASH Model
October 20-24, 2017
Archived Events
H. C. Wainwright 20th Annual Global Investment Conference
New York, NY – September 4-6, 2018 – Listen Here – Slides
JMP Securities Life Sciences Conference
New York, NY – June 21, 2018
Goldman Sachs 39th Annual Global Healthcare Conference
Rancho Palos Verdes, California – June 13, 2018
Review of Madrigal’s 36-week phase 2 results for MGL-3196
New York, NY – May 31, 2018 8:30am – Listen Here – Presentation
EASL International Liver Congress 2018
Paris, France – April 11-15, 2018 – Presentation Slides – Listen Here
HC Wainwright NASH Investor Conference 2018
New York, NY – March 19, 2018 – Webcast Link
The Cowen and Company 38th Annual Health Care Conference
Boston, MA – March 14th 2018 – Listen Here
Global NASH Congress
London, UK – February 26-27, 2018 – MGL-3196, a liver directed highly selective thyroid hormone receptor (THR) beta agonist for the treatment of NASH
More Archived Events …
Madrigal’s MGL-3196 Achieves Primary Endpoint in Patients with Heterozygous Familial Hypercholesterolemia (HeFH)
Conference Call & Webcast – February 8th, 2018 –
Listen Here
2018 NASH-TAG CONFERENCE
Thyroid Hormone Receptor Agonist – Becky Taub, MD
Park City, Utah – January 4-6, 2018 – Presentation Slides
Madrigal Announces Top-line Results from Phase 2 NASH Clinical Trial
Conference Call & Webcast – December 6 2017 8:30 am ET – Webcast link
Evercore ISI Biopharma Catalyst/Deep Dive Conference
Boston, MA – November 29-30, 2017 – Listen Here
Jefferies 2017 London Healthcare Conference
London, UK – November 15-16, 2017
FIRST EASL NAFLD SUMMIT
Vitamin D, thyroid function (the obvious and neglected; including Liver-Directed Thyroid Hormone Receptor-β (THR-β) agonists
Rome, Italy – November 9-11, 2017
AASLD Liver Meeting
Poster # 1969: MGL-3196, a β-Selective Thyroid Hormone Receptor (THR) Agonist, Demonstrates Metabolic, Anti-inflammatory and Anti-fibrotic Benefits in a Long-term High Fat Diet (HFD) Mouse NASH Model
Washington, DC – October 20-24, 2017
Discovery on Target Conference:
Thyroid Hormone Receptor Targets
Boston, MA – September 26, 2017
Cantor Fitzgerald Healthcare Conference
New York, NY – September 25-27, 2017
HC Wainwright / Rodman & Renshaw Annual Healthcare Conference
New York, NY – September 10-12, 2017
JMP Securities Life Sciences Conference
New York, NY – June 20-21, 2017
Jefferies 2017 Healthcare Conference
New York, NY – June 6-9, 2017
Jefferies 2018 Global Healthcare Conference
New York, NY – June 5-8, 2018 – Listen Here – Presentation
H.C. Wainwright NASH Investor Conference
New York, NY – April 3, 2017
ROTH Investor Conference
Laguna Niguel, CA – March 13, 2017
Cowen Healthcare Conference
Boston, MA – March 8, 2017
